Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29133799 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL24783631 | 0.76 | NCF1 (0.55) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL1998972 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL1486301 | 0.74 | CHEK1 (0.50) | KDM4EALDH1A1NPC1RAB9ACYP1A2 | |
| SCHEMBL969950 | 0.74 | NCF1 (0.59) | KDM4EALDH1A1MAPTHPGDNCF1 | |
| SCHEMBL5272072 | 0.73 | MAPT (0.50) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL224647 | 0.72 | KDM4E (0.46) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL12890445 | 0.72 | KDM4E (0.46) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL6006480 | 0.72 | KDM4E (0.39) | KDM4EALDH1A1MAPTGLAHPGD | |
| SCHEMBL13134266 | 0.69 | EGFR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242817-B | HIF1 alpha modulators purposes in treatment cancer | 菲布罗根公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-7960402-B2 | Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| CN-101500569-A | HIF hydroxylase inhibitors for treatment of anemia of cancer | FIBROGEN INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101420980-A | The Compounds and methods for of treatment apoplexy | FIBROGEN INC (US) | 2009-04-29 | — | — | CN | disclosed |
| EP-1795527-B1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-101242817-A | Use of HIF1 alpha modulators for treatment of cancer | FIBROGEN INC (US) | 2008-08-13 | — | — | CN | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | KDM4E 295/4885ALDH1A1 873/4885MAPT 4823/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | KDM4E 3385/4885ALDH1A1 2782/4885MAPT 2433/4885 |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | KDM4E 607/4885ALDH1A1 1954/4885MAPT 3685/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | KDM4E 295/4885ALDH1A1 873/4885MAPT 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.